MyFinsight
Home
Blog
About
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$3,431,736
Unit: Dollar
Positive Cash Flow Breakdown
Change in fair value of investme...
Net proceeds from issuance of se...
Proceeds from investment note r...
Others
Negative Cash Flow Breakdown
Net income (loss)
Investment in preferred stock an...
Gain on related party investment...
Others
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Cash Flow
2026-04-30
2025-04-30
Other non-cash income
-
0
Net income (loss)
-19,424,654
30,656,050
Gain on related party investment - qcls
2,089,000
-
Issuance costs series c preferred stock and warrants
1,234,553
-
Loss on issuance of series c preferred stock
215,000
-
Gain on re-fair value of warrants
106,000
-
Loss on long term asset
-
0
Non-cash interest income
162,500
300,000
Non-cash warrant liability
0
469,000
Intangible asset impairment
1,549,427
0
Stock issued for compensation - rsus
892,500
478,637
Stock-based compensation - options
236,056
-
Gain on related party investment - tnf
-
21,395,734
Unrealized (gain) loss on marketable equity securities
-412,306
66,316
Change in fair value of investment - tnf
-
5,063,950
Change in fair value of warrant liability
-4,746,135
10,446,000
Change in fair value of derivative liability
1,117,000
2,184,000
Change in fair value of warrants - tnf
-
-2,367,684
Change in fair value of convertible note receivable - femasys
1,304,000
941,000
Change in fair value of warrant assets - femasys
-2,581,000
-2,091,000
Change in fair value of investment - qcls
-7,732,000
-
Change in fair value of warrants - qcls
-1,379,000
-
(increase) decrease in prepaid expenses and other current assets
251,386
-36,041
Increase (decrease) in accounts payable
-128,102
9,835
Increase (decrease) in accrued expenses
-1,548,249
1,310,457
Net cash used in operating activities
-5,152,914
-2,978,296
Investment in preferred stock and warrants
-
7,000,000
Investment in preferred stock and warrants - qcls
3,000,000
-
Investment convertible note receivable and warrants
-
0
Proceeds from investment note receivable
5,000,000
-
Proceeds from issuance of preferred stock, net of transaction costs
-
0
Net cash provided by (used in) investing activities
2,000,000
-7,000,000
Repurchase of common stock, net
401,625
2,542,276
Net proceeds from issuance of series c preferred stock
6,182,447
-
Redemption of preferred stock
0
22,486,875
Payment of series c convertible preferred stock dividends
246,005
-
Net proceeds from warrant exercise
1,046,760
0
Net cash provided by (used in) financing activities
6,581,577
-25,029,151
Effect of currency rate exchange on cash and cash equivalents
3,073
-358
Net increase (decrease) in cash and cash equivalents
3,431,736
-35,007,805
Cash and cash equivalents at beginning of the year
15,172,163
-
Cash and cash equivalents at end of the year
18,603,899
-
Page 1
Unit: Dollar.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net proceeds from
issuance of series c...
$6,182,447
Net proceeds from
warrant exercise
$1,046,760
Proceeds from investment
note receivable
$5,000,000
Net cash provided by
(used in) financing...
$6,581,577
(126.30%↑ Y/Y)
Net cash provided by
(used in) investing...
$2,000,000
(128.57%↑ Y/Y)
Effect of currency rate
exchange on cash and cash...
$3,073
(958.38%↑ Y/Y)
Canceled cashflow
$647,630
Canceled cashflow
$3,000,000
Net increase
(decrease) in cash and cash...
$3,431,736
(109.80%↑ Y/Y)
Canceled cashflow
$5,152,914
Repurchase of common stock,
net
$401,625
(-84.20%↓ Y/Y)
Payment of series c
convertible preferred stock...
$246,005
Change in fair value of
investment - qcls
-$7,732,000
Change in fair value of
warrant liability
-$4,746,135
(-145.43%↓ Y/Y)
Change in fair value of
warrant assets - femasys
-$2,581,000
(-23.43%↓ Y/Y)
Intangible asset
impairment
$1,549,427
Change in fair value of
warrants - qcls
-$1,379,000
Issuance costs series c
preferred stock and...
$1,234,553
Stock issued for
compensation - rsus
$892,500
(86.47%↑ Y/Y)
Unrealized (gain) loss on
marketable equity...
-$412,306
(-721.73%↓ Y/Y)
Stock-based compensation -
options
$236,056
Loss on issuance of
series c preferred...
$215,000
Investment in preferred
stock and warrants -...
$3,000,000
Net cash used in
operating activities
-$5,152,914
(-73.02%↓ Y/Y)
Canceled cashflow
$20,977,977
Net income (loss)
-$19,424,654
(-163.36%↓ Y/Y)
Gain on related party
investment - qcls
$2,089,000
Increase (decrease) in
accrued expenses
-$1,548,249
(-218.15%↓ Y/Y)
Change in fair value of
convertible note receivable...
$1,304,000
(38.58%↑ Y/Y)
Change in fair value of
derivative liability
$1,117,000
(-48.86%↓ Y/Y)
(increase) decrease in
prepaid expenses and...
$251,386
(797.50%↑ Y/Y)
Non-cash interest income
$162,500
(-45.83%↓ Y/Y)
Increase (decrease) in
accounts payable
-$128,102
(-1402.51%↓ Y/Y)
Gain on re-fair value
of warrants
$106,000
Buy us a coffee